Jenapharm Gmbh & Co. Kg

Bayer Schering Pharma Ag

Lothar Sobek

Gerd Schubert

Sven Ring

Walter Elger

Birgitt Schneider

Sigfrid Schwarz

Vladimir Patchev

G&uuml;nter Kaufmann

Alexander Hillisch

Ulrich Bothe

Guenter Kaufmann

The present patent application relates to 11&#x3b2;-benzaldoxime derivatives of D-homooestra-4,9-dien-3-ones of formula I: wherein Compounds of formula I bind more strongly to the glucocorticoid receptor than to the progesterone receptor and are effective antiglucocorticoids. According to the invention, they are suitable for the treatment and/or prevention of symptoms and/or diseases that are attributable to an androgen deficiency induced by glucocorticoids, especially cortisol.

11&#x3b2;-benzaldoxime derivatives of D-homooestra-4,9-dien-3-ones

The novel glucocorticoid receptor antagonists are 11&#x3b2;-substituted steroid compounds of formula (I): wherein Rdenotes a methyl group, a methoxy group, or an ethoxy group; wherein Rdenotes a tert.-butyl group, a 1-hydroxy-1-methylethyl group, a 1-methoxy-1-methylethyl group, an ethyl isocrotonate group, or a substituted phenyl group. The method of treating an individual suffering from glucocorticoid-mediated hypogonadism, sexual dysfunctions, and/or infertility includes administering a daily dosage consisting of an effective amount of one of these 11&#x3b2;-substituted steroid compounds.

Glucocorticoid receptor antagonists for prophylaxis and therapy of glucocorticoid-mediated hypogonadism, of sexual dysfunction and/or infertility

The method of treating or preventing a disease in a human male or a male animal caused by a decreased production of androgens, such as testosterone, in the human male or male animal includes administering an effective amount of a glucocorticoid receptor antagonist to the human male or the male animal in order to increase production of the androgens. These diseases include male sexual dysfunction, infertility and hypogonadism. Novel androgen receptor antagonist compounds and methods of synthesis are also described.

Methods and compositions for treating diseases due to androgen deficiency with glucocorticoid receptor antagonist compounds and new compounds

Described are new, unsaturated 14,15-cyclopropano-androstanes of general formula (I) and their pharmaceutically acceptable salts, a process for their production and pharmaceutical preparations that contain these compounds. The compounds are characterized by hormonal (gestagenic and/or androgenic) activity and may be used for hormone replacement therapy.

Unsaturated 14, 15-cyclopropanoandrostanes, method for the production thereof and pharmaceutical preparations containing said compounds

Described are new 14,15-cyclopropano steroids of the 19-norandrostane series of general formula (I) and their pharmaceutically acceptable salts, a process for their production and pharmaceutical preparations that contain these compounds. The compounds are distinguished by hormonal (gestagenic and/or androgenic) activity.

14,15-cyclopropano steroids of the 19-norandrostane series, method for the production thereof and pharmaceutical preparations containing said compounds

Growing community of inventors

Jena, Germany

Lothar Sobek